Amylyx Pharmaceuticals, Inc. (AMLX)
A+
Pipeline Grade
Financial Position (from SEC Filings)
$230.1M
Cash & Equivalents
$36.9M
Quarterly Burn Rate
19 mo
Est. Cash Runway
$1,976M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (1 Assets)
| Drug | Phase | Indications |
|---|---|---|
|
SODIUM PHENYLBUTYRATE, TAURURSODIOL
RELYVRIO |
NDA | ALS, Alzheimer Disease, Amyotrophic Lateral Sclerosis, Atypical Parkinsonism, Central Nervous System Diseases, Motor Neuron Disease, Nervous System Diseases, Neurodegenerative Diseases, Neuromuscular Diseases, Post Bariatric Hypoglycemia, Progressive Supranuclear Palsy, PSP, Spinal Cord Diseases, TDP-43 Proteinopathies, Wolfram Syndrome |
Upcoming Catalysts
| Date | Event | Drug |
|---|---|---|
| 2027-02-01 | Phase1 Readout | — |
Active Clinical Trials (4)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT06747468 | Avexitide for Treatment of Post-Bariatric Hypoglycemia | PHASE3 | Active Not Recruiting | 75 |
| NCT05021536 | Phase III Trial of AMX0035 for Amyotrophic Lateral Sclerosis Treatment | PHASE3 | Active Not Recruiting | 664 |
| NCT05676034 | AMX0035 in Adult Patients With Wolfram Syndrome | PHASE2 | Active Not Recruiting | 12 |
| NCT06665165 | AMX0114 in Adult Participants With Amyotrophic Lateral Sclerosis | PHASE1 | Recruiting | 48 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.